https://stock.noler.com/us/stock/pharmacyclics-inc https://stock.noler.com/us/stock/pharmacyclics-inc/accounts-payable https://stock.noler.com/us/stock/pharmacyclics-inc/accounts-payable-trade-current https://stock.noler.com/us/stock/pharmacyclics-inc/accounts-receivable https://stock.noler.com/us/stock/pharmacyclics-inc/accounts-receivable-gross-current https://stock.noler.com/us/stock/pharmacyclics-inc/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/pharmacyclics-inc/accrued-employee-benefits-current https://stock.noler.com/us/stock/pharmacyclics-inc/accrued-income-taxes-current https://stock.noler.com/us/stock/pharmacyclics-inc/accrued-liabilities-current https://stock.noler.com/us/stock/pharmacyclics-inc/accrued-marketing-costs-current https://stock.noler.com/us/stock/pharmacyclics-inc/accrued-royalties-current-and-noncurrent https://stock.noler.com/us/stock/pharmacyclics-inc/accumulated-depreciation https://stock.noler.com/us/stock/pharmacyclics-inc/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/pharmacyclics-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/pharmacyclics-inc/additional-paid-in-capital https://stock.noler.com/us/stock/pharmacyclics-inc/advances-on-inventory-purchases https://stock.noler.com/us/stock/pharmacyclics-inc/advertising-expense https://stock.noler.com/us/stock/pharmacyclics-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/pharmacyclics-inc/amended-reports-10-k https://stock.noler.com/us/stock/pharmacyclics-inc/amended-reports-10-q https://stock.noler.com/us/stock/pharmacyclics-inc/amortization https://stock.noler.com/us/stock/pharmacyclics-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/pharmacyclics-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/pharmacyclics-inc/aoci https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-current https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-debt-maturities-within-one-year-amortized-cost https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-debt-maturities-within-one-year-fair-value https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-fair-value-disclosure https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-gross-realized-gain-loss-excluding-other-than-temporary-impairments https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-gross-unrealized-gain https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-gross-unrealized-losses https://stock.noler.com/us/stock/pharmacyclics-inc/available-for-sale-securities https://stock.noler.com/us/stock/pharmacyclics-inc/basic-shares https://stock.noler.com/us/stock/pharmacyclics-inc/capital-expenditures https://stock.noler.com/us/stock/pharmacyclics-inc/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/pharmacyclics-inc/capital-lease-obligations-incurred https://stock.noler.com/us/stock/pharmacyclics-inc/cash-and-equivalents https://stock.noler.com/us/stock/pharmacyclics-inc/cash-flow-breakdown https://stock.noler.com/us/stock/pharmacyclics-inc/certificates-of-deposit-at-carrying-value https://stock.noler.com/us/stock/pharmacyclics-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmacyclics-inc/common-stock-value https://stock.noler.com/us/stock/pharmacyclics-inc/comprehensive-income https://stock.noler.com/us/stock/pharmacyclics-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/pharmacyclics-inc/construction-in-progress-gross https://stock.noler.com/us/stock/pharmacyclics-inc/contracts-revenue https://stock.noler.com/us/stock/pharmacyclics-inc/cost-of-goods-sold https://stock.noler.com/us/stock/pharmacyclics-inc/costs-and-expenses https://stock.noler.com/us/stock/pharmacyclics-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/pharmacyclics-inc/current-assets https://stock.noler.com/us/stock/pharmacyclics-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/pharmacyclics-inc/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/pharmacyclics-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmacyclics-inc/current-liabilities https://stock.noler.com/us/stock/pharmacyclics-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/pharmacyclics-inc/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-revenue https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-investments https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/pharmacyclics-inc/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/pharmacyclics-inc/defined-contribution-plan-cost-recognized https://stock.noler.com/us/stock/pharmacyclics-inc/depreciation-and-amortization https://stock.noler.com/us/stock/pharmacyclics-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/pharmacyclics-inc/development-stage-enterprise-deficit-accumulated-during-development-stage https://stock.noler.com/us/stock/pharmacyclics-inc/diluted-shares https://stock.noler.com/us/stock/pharmacyclics-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/pharmacyclics-inc/effective-tax-rate https://stock.noler.com/us/stock/pharmacyclics-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/pharmacyclics-inc/employee-stock-ownership-plan-esop-weighted-average-purchase-price-of-shares-purchased https://stock.noler.com/us/stock/pharmacyclics-inc/eps https://stock.noler.com/us/stock/pharmacyclics-inc/eps-basic https://stock.noler.com/us/stock/pharmacyclics-inc/excess-tax-benefit-from-share-based-compensation-financing-activities https://stock.noler.com/us/stock/pharmacyclics-inc/excess-tax-benefit-from-share-based-compensation-operating-activities https://stock.noler.com/us/stock/pharmacyclics-inc/fair-value-inputs-discount-rate https://stock.noler.com/us/stock/pharmacyclics-inc/financing-cash-flow https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-amortization-expense-remainder-of-fiscal-year https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/pharmacyclics-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/pharmacyclics-inc/foreign-earnings https://stock.noler.com/us/stock/pharmacyclics-inc/furniture-and-fixtures-gross https://stock.noler.com/us/stock/pharmacyclics-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/pharmacyclics-inc/gain-loss-on-disposition-of-property https://stock.noler.com/us/stock/pharmacyclics-inc/general-and-administrative-expense https://stock.noler.com/us/stock/pharmacyclics-inc/impairment-of-long-lived-assets-held-for-use https://stock.noler.com/us/stock/pharmacyclics-inc/income-tax https://stock.noler.com/us/stock/pharmacyclics-inc/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/pharmacyclics-inc/income-taxes-paid https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-accrued-income-taxes-payable https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-accrued-taxes-payable https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-other-deferred-liability https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-other-noncurrent-liabilities https://stock.noler.com/us/stock/pharmacyclics-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/pharmacyclics-inc/insider-transactions-other https://stock.noler.com/us/stock/pharmacyclics-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/pharmacyclics-inc/insider-transactions-stock-options/purchases https://stock.noler.com/us/stock/pharmacyclics-inc/insider-transactions-stock-options/sales https://stock.noler.com/us/stock/pharmacyclics-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/pharmacyclics-inc/interest-and-other-income https://stock.noler.com/us/stock/pharmacyclics-inc/interest-paid https://stock.noler.com/us/stock/pharmacyclics-inc/inventory https://stock.noler.com/us/stock/pharmacyclics-inc/inventory-finished-goods-net-of-reserves https://stock.noler.com/us/stock/pharmacyclics-inc/inventory-raw-materials-net-of-reserves https://stock.noler.com/us/stock/pharmacyclics-inc/inventory-work-in-process-net-of-reserves https://stock.noler.com/us/stock/pharmacyclics-inc/investing-cash-flow https://stock.noler.com/us/stock/pharmacyclics-inc/investment-income-interest https://stock.noler.com/us/stock/pharmacyclics-inc/investment-income-net-amortization-of-discount-and-premium https://stock.noler.com/us/stock/pharmacyclics-inc/issuance-of-stock-and-warrants-for-services-or-claims https://stock.noler.com/us/stock/pharmacyclics-inc/lease-and-rental-expense https://stock.noler.com/us/stock/pharmacyclics-inc/leasehold-improvements-gross https://stock.noler.com/us/stock/pharmacyclics-inc/license-and-services-revenue https://stock.noler.com/us/stock/pharmacyclics-inc/license-costs https://stock.noler.com/us/stock/pharmacyclics-inc/machinery-and-equipment-gross https://stock.noler.com/us/stock/pharmacyclics-inc/marketable-securities-realized-gain-loss-excluding-other-than-temporary-impairments https://stock.noler.com/us/stock/pharmacyclics-inc/maturities-of-available-for-sale-securities https://stock.noler.com/us/stock/pharmacyclics-inc/money-market-funds-at-carrying-value https://stock.noler.com/us/stock/pharmacyclics-inc/net-change-in-cash https://stock.noler.com/us/stock/pharmacyclics-inc/net-income https://stock.noler.com/us/stock/pharmacyclics-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/pharmacyclics-inc/operating-cash-flow https://stock.noler.com/us/stock/pharmacyclics-inc/operating-expenses https://stock.noler.com/us/stock/pharmacyclics-inc/operating-income https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due-in-four-and-five-years https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due-in-two-and-three-years https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/pharmacyclics-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/pharmacyclics-inc/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/pharmacyclics-inc/operating-leases-rent-expense-minimum-rentals https://stock.noler.com/us/stock/pharmacyclics-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/pharmacyclics-inc/other-noncash-expense https://stock.noler.com/us/stock/pharmacyclics-inc/other-noncurrent-assets https://stock.noler.com/us/stock/pharmacyclics-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/pharmacyclics-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/pharmacyclics-inc/paid-in-capital-other https://stock.noler.com/us/stock/pharmacyclics-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/pharmacyclics-inc/paid-in-capital-tax-effect-from-share-based-compensation https://stock.noler.com/us/stock/pharmacyclics-inc/patents-pending https://stock.noler.com/us/stock/pharmacyclics-inc/payments-for-proceeds-from-other-investing-activities https://stock.noler.com/us/stock/pharmacyclics-inc/payments-for-proceeds-from-removal-costs https://stock.noler.com/us/stock/pharmacyclics-inc/payments-to-acquire-available-for-sale-securities https://stock.noler.com/us/stock/pharmacyclics-inc/payments-to-acquire-in-process-research-and-development https://stock.noler.com/us/stock/pharmacyclics-inc/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/pharmacyclics-inc/preferred-shares-facts https://stock.noler.com/us/stock/pharmacyclics-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmacyclics-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/pharmacyclics-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/pharmacyclics-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/pharmacyclics-inc/preferred-stock-value https://stock.noler.com/us/stock/pharmacyclics-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/pharmacyclics-inc/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/pharmacyclics-inc/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/pharmacyclics-inc/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans-including-stock-options https://stock.noler.com/us/stock/pharmacyclics-inc/proceeds-from-notes-payable https://stock.noler.com/us/stock/pharmacyclics-inc/proceeds-from-related-party-debt https://stock.noler.com/us/stock/pharmacyclics-inc/proceeds-from-sale-and-maturity-of-available-for-sale-securities https://stock.noler.com/us/stock/pharmacyclics-inc/proceeds-from-sale-of-available-for-sale-securities https://stock.noler.com/us/stock/pharmacyclics-inc/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/pharmacyclics-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/pharmacyclics-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/pharmacyclics-inc/property-plant-equipment https://stock.noler.com/us/stock/pharmacyclics-inc/provision-for-doubtful-accounts https://stock.noler.com/us/stock/pharmacyclics-inc/public-float https://stock.noler.com/us/stock/pharmacyclics-inc/purchase-obligation https://stock.noler.com/us/stock/pharmacyclics-inc/repayments-of-debt-and-capital-lease-obligations https://stock.noler.com/us/stock/pharmacyclics-inc/repayments-of-notes-payable https://stock.noler.com/us/stock/pharmacyclics-inc/research-and-development https://stock.noler.com/us/stock/pharmacyclics-inc/research-and-development-expense-excluding-acquired-in-process-cost https://stock.noler.com/us/stock/pharmacyclics-inc/research-and-development-in-process https://stock.noler.com/us/stock/pharmacyclics-inc/retained-earnings https://stock.noler.com/us/stock/pharmacyclics-inc/revenue https://stock.noler.com/us/stock/pharmacyclics-inc/sale-of-stock-price-per-share https://stock.noler.com/us/stock/pharmacyclics-inc/sales-allowances-goods https://stock.noler.com/us/stock/pharmacyclics-inc/sales-and-excise-tax-payable-current-and-noncurrent https://stock.noler.com/us/stock/pharmacyclics-inc/sales-returns-and-allowances-goods https://stock.noler.com/us/stock/pharmacyclics-inc/sales-revenue-goods-gross https://stock.noler.com/us/stock/pharmacyclics-inc/sales-revenue-goods-net https://stock.noler.com/us/stock/pharmacyclics-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/pharmacyclics-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-10-k https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-10-k405 https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-10-kt https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-10-q https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-15-12g https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-25-nse https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-425 https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-8-a12g https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-8-k https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-ars https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-ct-order https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-def-14a https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-defa14a https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-defr14a https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-pre-14a https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-sc-14d9 https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-sc-14f1 https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-sc-to-t https://stock.noler.com/us/stock/pharmacyclics-inc/sec-filings-sc14d9c https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-424b1 https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-424b2 https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-424b3 https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-424b4 https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-424b5 https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-effect https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-posasr https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-rw https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-s-1 https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-s-3asr https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-s-3mef https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/pharmacyclics-inc/secondary-offerings-form-s-8-pos https://stock.noler.com/us/stock/pharmacyclics-inc/sga-expense https://stock.noler.com/us/stock/pharmacyclics-inc/share-based-compensation-shares-authorized-under-stock-option-plans-exercise-price-range-exercisable-options-average-exercise-price https://stock.noler.com/us/stock/pharmacyclics-inc/share-based-compensation-shares-authorized-under-stock-option-plans-exercise-price-range-number-of-exercisable-options https://stock.noler.com/us/stock/pharmacyclics-inc/share-based-compensation-shares-authorized-under-stock-option-plans-exercise-price-range-number-of-outstanding-options https://stock.noler.com/us/stock/pharmacyclics-inc/share-based-compensation-shares-authorized-under-stock-option-plans-exercise-price-range-outstanding-options-average-exercise-price-beginning-balance https://stock.noler.com/us/stock/pharmacyclics-inc/share-price https://stock.noler.com/us/stock/pharmacyclics-inc/shareholders-equity https://stock.noler.com/us/stock/pharmacyclics-inc/shares-authorized https://stock.noler.com/us/stock/pharmacyclics-inc/shares-issued https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-aggregate-intrinsic-value-outstanding https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-forfeited-in-period https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-forfeitures-grant-date-fair-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-grants-in-period https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-nonvested-grant-date-fair-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-nonvested-number https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-vested-in-period https://stock.noler.com/us/stock/pharmacyclics-inc/stock-award-rsu-vested-in-period-grant-date-fair-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-based-compensation https://stock.noler.com/us/stock/pharmacyclics-inc/stock-compensation-allocation-of-recognized-period-costs-capitalized-amount https://stock.noler.com/us/stock/pharmacyclics-inc/stock-compensation-tax-benefit-from-compensation-expense https://stock.noler.com/us/stock/pharmacyclics-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/pharmacyclics-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/pharmacyclics-inc/stock-issued-shares-issued-shares-espps https://stock.noler.com/us/stock/pharmacyclics-inc/stock-issued-shares-issued-shares-new-issues https://stock.noler.com/us/stock/pharmacyclics-inc/stock-issued-shares-issued-value-issued-for-noncash-considerations https://stock.noler.com/us/stock/pharmacyclics-inc/stock-issued-shares-issued-value-other https://stock.noler.com/us/stock/pharmacyclics-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/pharmacyclics-inc/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-vested-and-expected-to-vest-exercisable-aggregate-intrinsic-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-vested-and-expected-to-vest-exercisable-average-exercise-price https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-vested-and-expected-to-vest-exercisable-number https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/pharmacyclics-inc/stock-options-vested-in-period-fair-value-1 https://stock.noler.com/us/stock/pharmacyclics-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/pharmacyclics-inc/tax-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/pharmacyclics-inc/tax-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/pharmacyclics-inc/tax-reconciliation-other-reconciling-items https://stock.noler.com/us/stock/pharmacyclics-inc/tax-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/pharmacyclics-inc/tax-reconciliation-tax-credits-research https://stock.noler.com/us/stock/pharmacyclics-inc/tax-withholding-on-stock-awards https://stock.noler.com/us/stock/pharmacyclics-inc/taxes-payable-current https://stock.noler.com/us/stock/pharmacyclics-inc/total-assets https://stock.noler.com/us/stock/pharmacyclics-inc/total-liabilities https://stock.noler.com/us/stock/pharmacyclics-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/pharmacyclics-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/pharmacyclics-inc/us-government-securities-at-carrying-value https://stock.noler.com/us/stock/pharmacyclics-inc/utb-decrease-from-prior-year-positions https://stock.noler.com/us/stock/pharmacyclics-inc/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/pharmacyclics-inc/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/pharmacyclics-inc/utb-increase-from-settlements https://stock.noler.com/us/stock/pharmacyclics-inc/utb-reduction-from-statute-lapse https://stock.noler.com/us/stock/pharmacyclics-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/pharmacyclics-inc/valuation-allowances-and-reserves-adjustments https://stock.noler.com/us/stock/pharmacyclics-inc/valuation-allowances-and-reserves-balance https://stock.noler.com/us/stock/pharmacyclics-inc/valuation-allowances-and-reserves-charged-to-other-accounts https://stock.noler.com/us/stock/pharmacyclics-inc/valuation-allowances-and-reserves-deductions https://stock.noler.com/us/stock/pharmacyclics-inc/weighted-average-number-of-share-outstanding-basic-and-diluted